Meghpara Sanket, Chohan Moeed, Bandyopadhyay Anuja, Kozlowski Conrad, Casinas Jameson, Kushida Clete, Camacho Macario
Department of Internal Medicine, Tripler Army Medical Center, Honolulu, HI, USA.
Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Expert Rev Respir Med. 2022 Mar;16(3):285-291. doi: 10.1080/17476348.2021.2001332. Epub 2021 Nov 22.
Myofunctional therapy (MT) improves obstructive sleep apnea (OSA) in patients.
We systematically reviewed publications to evaluate MT as a treatment for OSA. We identified relevant articles and performed a meta-analysis on apnea-hypopnea index (AHI) scores, lowest oxygen saturation (LSAT), and Epworth Sleepiness Scale (ESS). Search databases were retained as primary data sources with the search performed through 18 June 2021.
Fifteen studies with 237 patients provided OSA outcomes before and after MT, which were analyzed for this meta-analysis. The mean AHI scores decreased from 28.0 ± 16.2/h to 18.6 ± 13.1/h. The AHI standard mean difference (SMD) is -1.34 (large effect) [95% CI -0.84, -1.85], (P < 0.00001). LSAT (197 patients) improved from 83.18 ± 6.10% to 85.13 ± 7.01%. The LSAT SMD is 0.44 [95% CI 0.75, 0.12], (P < 0.007). Sleepiness measured via ESS (156 patients) demonstrated a decrease from 12.71 ± 5.73 to 8.78 ± 5.80. The ESS SMD is -1.0 [95% CI -0.50, -1.50], (P < 0.0001).
肌功能治疗（MT）可改善患者的阻塞性睡眠呼吸暂停（OSA）。
我们系统地回顾了相关文献，以评估MT作为OSA治疗方法的效果。我们检索了相关文章，并对呼吸暂停低通气指数（AHI）评分、最低血氧饱和度（LSAT）和爱泼华嗜睡量表（ESS）进行了荟萃分析。检索数据库作为主要数据源，检索截至2021年6月18日。
15项研究共237例患者提供了MT治疗前后的OSA结果，并纳入本次荟萃分析。平均AHI评分从28.0±16.2次/小时降至18.6±13.1次/小时。AHI的标准平均差（SMD）为-1.34（效果显著）[95%置信区间-0.84，-1.85]，（P<0.00001）。LSAT（197例患者）从83.18±6.1%提高到85.13±7.01%。LSAT的SMD为0.44[95%置信区间0.75，0.12]，（P<0.007）。通过ESS评估的嗜睡程度（156例患者）从12.71±5.73降至8.78±5.80。ESS的SMD为-1.0[95%置信区间-0.50，-1.50]，（P<0.0001）。
